Paul N. Staats

Paul N. Staats

Auto-generated profile, based on publicly available information

Paul N. Staats

Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Pathology
Verified
Journal Article
Closed access
PDF file
SLSandy Liu
Sandy Liu
PSPaul Staats
Paul Staats
MLMichael Lee
Michael Lee
HAH. Richard Alexander
H. Richard Alexander
ABAllen P. Burke
Allen P. Burke

27 November 2013 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
NKNamita Kundu
Namita Kundu
XMXinrong Ma
Xinrong Ma
TKTyler Kochel
Tyler Kochel
Olga GoloubevaOlga Goloubeva
Olga Goloubeva
PSPaul Staats
Paul Staats
AFAmy Fulton
Amy Fulton
The cyclooxygenase pathway is strongly implicated in breast cancer progression but the role of this pathway in the biology of breast cancer stem/progenitor cells has not been defined. Recent attention has focused on targeting the cyclooxygenase 2 (COX-2) pathway downstream of the COX-2 enzyme by blocking the activities of individual prostaglandin E (EP) receptors. Prostaglandin E receptor 4 (EP4) is widely expressed in primary invasive ductal carcinomas of the breast and antagonizing this receptor with small molecule inhibitors or shRNA directed to EP4 inhibits metastatic potential in both syngeneic and xenograft models. Breast cancer stem/progenitor cells are defined as a subpopulation of cells that drive tumor growth, metastasis, treatment resistance, and relapse. Mammosphere-forming breast cancer cells of human (MDA-MB-231, SKBR3) or murine (66.1, 410.4) origin of basal-type, Her-2 phenotype and/or with heightened metastatic capacity upregulate expression of both EP4 and COX-2 and are more tumorigenic compared to the bulk population. In contrast, luminal-type or non-metastatic counterparts (MCF7, 410, 67) do not increase COX-2 and EP4 expression in mammosphere culture. Treatment of mammosphere-forming cells with EP4 inhibitors (RQ-15986, AH23848, Frondoside A) or EP4 gene silencing, but not with a COX inhibitor (Indomethacin) reduces both mammosphere-forming capacity and the expression of phenotypic markers (CD44hi/CD24low, aldehyde dehydrogenase) of breast cancer stem cells. Finally, an orally delivered EP4 antagonist (RQ-08) reduces the tumor-initiating capacity and markedly inhibits both the size of tumors arising from transplantation of mammosphere-forming cells and phenotypic markers of stem cells in vivo. These studies support the continued investigation of EP4 as a potential therapeutic target and provide new insight regarding the role of EP4 in supporting a breast cancer stem cell/tumor-initiating phenotype.

18 December 2013 in Cancer Cytopathology
Verified
Journal Article
Closed access
PDF file
AFAdele D. Fung
Adele D. Fung
JCJennifer A. Collins
Jennifer A. Collins
CCChristina Campassi
Christina Campassi
OIOlga B. Ioffe
Olga B. Ioffe
PSPaul N. Staats
Paul N. Staats

1 December 2014 in Pathology
Verified
Journal Article
Closed access
PSPaul Staats
Paul Staats
FTFABIO FERNANDES TAVORA
FABIO FERNANDES TAVORA
ABAllen P. Burke
Allen P. Burke

1 May 2014 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
PSPaul N. Staats
Paul N. Staats
WMW. Glenn FRCPath McCluggage
W. Glenn FRCPath McCluggage
PCPhilip B. Clement
Philip B. Clement
RYRobert H. Young
Robert H. Young
Primary intestinal-type glandular lesions of the vagina are rare. We report a series of 14 lesions, including 1 intestinal-type polyp without neoplastic features, 3 adenomas (2 with high-grade dysplasia), and 10 adenocarcinomas. Patients ranged in age from 20 to 86 years (mean 60 y) and presented with vaginal bleeding or a mass. No history of diethylstilbestrol exposure, adenosis, or endometriosis was elicited in any patient. The lesions were mostly polypoid, small (0.8 to 2.0 cm), and located in the posterior (6 cases) and lower (7 cases) vagina. One carcinoma metastasized to a para-aortic lymph node; the others were confined to the vagina. The neoplasms exhibited histologic features identical to those seen in primary large intestinal tumors, including variable numbers of goblet cells and in 1 case neuroendocrine cells. Five of the adenocarcinomas contained areas consistent with a precursor adenoma. In 3 cases, a benign urothelium-lined duct was adjacent to the lesion, and in 2 patients benign intestinal-type epithelium was present; no other potential benign precursor lesions were seen. Immunohistochemical analysis was performed on 6 cases; the tumors were positive for CDX-2 (6/6), CK20 (5/6), CEA (5/5), CK7 (4/6), and CA-125 (2/4) and were negative for ER (0/6) and p16 (0/2). Clinical outcome data were available in 3 patients with adenocarcinomas; 1 died of disease in <1 year, and 2 were alive with no evidence of disease at 2 and 7 years. The pertinent literature is reviewed, and the potential origin and differential diagnosis of these lesions are discussed.

31 May 2019 in Cancer Cytopathology
Verified
Journal Article
Closed access
PDF file
KCKrista Chain
Krista Chain
TLTeklu Legesse
Teklu Legesse
JHJonathon E. Heath
Jonathon E. Heath
PSPaul N. Staats
Paul N. Staats